This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meadows, T. A. Articles by Bhatt, D. L. Search for Related Content PubMed PubMed Citation Articles by Meadows, T. A. Articles by Bhatt, D. L. Related Collections Acute coronary syndromes Cerebrovascular disease/stroke Peripheral vascular disease Platelet function inhibitors Platelets Primary prevention Secondary prevention

(Circulation Research. 2007;100:1261.)
© 2007 American Heart Association, Inc.

Reviews

Clinical Aspects of Platelet Inhibitors and Thrombus Formation

Telly A. Meadows, Deepak L. Bhatt

From the Department of Cardiovascular Medicine, Cleveland Clinic, Ohio.

Correspondence to Deepak L. Bhatt, MD, Associate Director, Cleveland Clinic Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195. E-mail bhattd{at}ccf.org

This Review is part of a thematic series on Mechanisms, Models, and In Vivo Imaging of Thrombus Formation, which includes the following articles:

Activation of Platelet Function Through G Protein–Coupled Receptors

Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease

In Vivo Thrombus Formation in Murine Models

Clinical Aspects of Platelet Inhibitors and Thrombus Formation

Platelet Adhesion
Bernhard Nieswandt and Ulrich Walter Guest Editors

The platelet, once thought to be solely involved in clot formation, is now known to be a key mediator in various others processes such as inflammation, thrombosis, and atherosclerosis. Supported by the wealth of evidence from clinical trials demonstrating their benefits in patient outcomes, antiplatelet agents have become paramount in the prevention and management of various diseases involving the cardiovascular, cerebrovascular, and peripheral arterial systems. Despite being among the most widely used and studied classes of medical therapies, new discoveries regarding important clinical aspects and properties of these agents continue to be made. As our understanding of platelet biology expands, more effective and safer novel therapies continue to be developed. The use of more refined agents in conjunction with a better understanding of their effects will further the ability to provide more optimized care on an individual basis.

Key Words: antiplatelet therapy • thrombosis • platelets • atherosclerosis • cardiovascular disease

This article has been cited by other articles:

				R. Pawlinski, M. Tencati, C. R. Hampton, D. Spring, T. H. Pohlman, E. D. Verrier, T. Shishido, T. A. Bullard, L. M. Casey, J.-i. Abe, et al. Response to Letter Regarding Article, "Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy" Circulation, June 17, 2008; 117(24): e496 - e496. [Full Text] [PDF]

				C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers Review: Aspirin and Diabetes Mellitus: revisiting an old player Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 37 - 42. [Abstract] [PDF]

				C. Gachet and B. Aleil Testing antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34. [Abstract] [Full Text] [PDF]

				D. L. Bhatt Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis N. Engl. J. Med., November 15, 2007; 357(20): 2078 - 2081. [Full Text] [PDF]